Replies to post #957 on Biotech Values

[mskatiescarletohara]

OT: Mid-Swe...OXGN.

How long have you been following OXGN?

I ask because BMY terminated their R&D collaboration with OXGN just before OXGN held a CC addressing the Phase I studies, I believe in late 2000/2001. Do you know why BMY terminated the agreement? It was never disclosed to my knowledge, and sometimes these issues are not broadcast. Is it possible BMY had a problem with the cardiac toxicity, I listened to the CC and I remember that issue being discussed thoroughly. I believe that was when OXGN announced they would conduct another Phase I study to address the cardiac issues.

Also, are you in MAXM?

katie...